{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:04:46Z","timestamp":1789718686006,"version":"4.0.1"},"reference-count":15,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.1080\/13543784.2026.2724869","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:02:09Z","timestamp":1787839329000},"page":"643-646","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["HLD-0915: Could it be the breakthrough drug we need for metastatic prostate cancer?"],"prefix":"10.1080","volume":"35","author":[{"given":"Jakob R.","family":"Nypaver","sequence":"first","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02221-4"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2014.18"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107234"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.06.013"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2024.07.005"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5119"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.7_suppl.161"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.017"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5011"},{"issue":"1","key":"e_1_3_4_12_1","first-page":"EVIDoa2300171","article-title":"Targeted inhibition of CYP11A1 in castration-resistant prostate cancer","volume":"3","author":"Fizazi K","year":"2024","unstructured":"Fizazi K, Bernard-Tessier A, Roubaud G, et al. Targeted inhibition of CYP11A1 in castration-resistant prostate cancer. NEJM Evid. 2024;3(1):EVIDoa2300171.","journal-title":"NEJM Evid"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5060"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103774"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5115"},{"key":"e_1_3_4_16_1","volume-title":"AACR-NCI-EORTIC International Conference on Molecular Targets And Cancer Therapeutics","author":"Hahn AH","year":"2025","unstructured":"Preliminary safety, pharmacokinetics, and antitumor activity of HLD-0915, a first-in-class oral RIPTAC binding androgen receptor (AR) and bromodomain 4 (BRD4), in patients with metastatic castrate resistant prostate cancer (mCRPC). In: Hahn AH, Sahota S, Wang JS, editors. AACR-NCI-EORTIC International Conference on Molecular Targets And Cancer Therapeutics; Boston, MA; 2025."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505725"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2724869","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543784.2026.2724869","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2724869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:56:03Z","timestamp":1789718163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2724869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,2]]}},"alternative-id":["10.1080\/13543784.2026.2724869"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2724869","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}